Last reviewed · How we verify

CCTU — Portfolio Competitive Intelligence Brief

CCTU pipeline: 0 marketed, 0 filed, 7 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 7 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Experimental drug: Dexamethasone Experimental drug: Dexamethasone phase 3
Standard: Aprepitant Standard: Aprepitant phase 3 NK1 receptor antagonist NK1 receptor Oncology
Experimental drug: Aprepitant Experimental drug: Aprepitant phase 3 NK1 receptor antagonist NK1 receptor (neurokinin-1 receptor) Oncology / Supportive Care
Standard: Ondansetron Standard: Ondansetron phase 3 Serotonin 5-HT3 receptor antagonist 5-HT3 receptor Oncology
Experimental drug: Olanzapine Experimental drug: Olanzapine phase 3 Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor Psychiatry/Neurology
Experimental drug: Ondansetron Experimental drug: Ondansetron phase 3 5-HT3 receptor antagonist 5-HT3 receptor Oncology, Gastroenterology, Anesthesia
Standard: Dexamethasone Standard: Dexamethasone phase 3 Corticosteroid Glucocorticoid receptor Oncology, Rheumatology, Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 4 shared drug classes
  2. Montefiore Medical Center · 2 shared drug classes
  3. AstraZeneca · 2 shared drug classes
  4. Acacia Pharma Ltd · 2 shared drug classes
  5. Eli Lilly and Company · 2 shared drug classes
  6. Merck Sharp & Dohme LLC · 2 shared drug classes
  7. AbbVie · 2 shared drug classes
  8. Organon and Co · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for CCTU:

Cite this brief

Drug Landscape (2026). CCTU — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cctu. Accessed 2026-05-13.

Related